Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2020

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Pharma intelligence for marketing agencies

Gain insight into the pharmaceutical market landscape – we’ll help you communicate complex ideas clearly and develop customer-centric propositions.

Supporting market access strategy

With the pharma and healthcare sector facing increasing challenges, your clients rely more than ever on independent intelligence. As a marketer, you have to engage with multiple audiences across a variety of channels and to communicate complex information simply and persuasively.

We give you the means to identify future innovation and new market opportunities, develop customer-centric propositions, and keep a close eye on competitors. We can also help with branding, multi-channel communication and more.

What we offer

As the trusted partner of the top 50 pharmaceutical companies and 10 contract research organizations, our pharma intelligence will help you build a complete picture of the market and get access to past, current and future trends and analysis.

How it helps

You’ll get cutting-edge insights on the size and shape of markets, competitive threats, actionable customer perceptions and industry innovations.

Our accurate, reliable intelligence will help you:

Access in-depth knowledge from drug discovery to market access
Acquire a comprehensive understanding of the global pharma market
Get in-depth coverage of the entire pharmaceutical value-chain

Our unique strengths

Understand your clients’ world

Gain comprehensive knowledge of the global pharma market with our complete coverage.

Think ahead

Respond to market events, identify opportunities and anticipate changes by tracking updates impacting the pharmaceutical industry.

Deliver tailored solutions

Use our data and insight to create solutions to suit your clients’ needs.

Benefit from a dedicated service

Our services come with dedicated client service and analyst support.

View more
View Less

Relevant products

HBW Insight: Health, Beauty and Wellness

The single most comprehensive consumer healthcare information source covering regulatory, legislative, legal and commercial news across the over the counter medicines, vitamins and dietary supplements, and cosmetics industries.

Key benefits:

Get a global view
Be the first to know
Go beyond the news

Generics Bulletin

A well-respected and trusted industry source for the last 15 years, Generics Bulletin from Informa Pharma Intelligence provides in-depth news and analysis on issues that matter most to businesses across the generics, biosimilars and value-added medicines industries.

Key benefits:

Ask-the-Analyst™ Service
A powerful online platform
In-depth content coverage

Pink Sheet: global policy and regulatory coverage

Unparalleled access to global pharma regulatory and compliance intelligence and expertise.

Key benefits:

Get a global view
Go beyond the news
Hear from news makers

View all content

HBW Insight

No Plans To Remove CBD Products From Shelves, Says UK Food Regulator

By David Ridley 29 Jan 2020

CBD products already on the UK market are safe for now, as the country's Food Standards Agency says it will not take action while it works out how to implement the new European Union novel food regulations.

View article
Generics Bulletin

Who’s Hired? Sandoz Germany Seeks A New Country Head

By Akriti Seth 29 Jan 2020

While Sandoz looks for a new country head in Germany, Lupin has appointed a new chief corporate development officer and a Coherus executive has left the firm.

Topic Business Strategies

View article
Datamonitor Healthcare

Datamonitor Healthcare's Top Research Reports

29 Jan 2020

View white paper
Datamonitor Healthcare

Cardiovascular Disease Epidemiology Overview

By Niharika Dandamudi 28 Jan 2020

Cardiovascular Diseases (CVDs) are one of the leading causes of disease burden worldwide. This epidemiology overview presents the prevalence of some CVDs and their associated clinical risk factors analyzed by Datamonitor Healthcare.

View infographic
Biomedtracker, Datamonitor Healthcare

2019 Post-ASH Conference Report Extract

28 Jan 2020

Access vital post-ASH meeting reporting from the expert analysts at Datamonitor Healthcare and Biomedtracker.

Single report
Pink Sheet

EU Countries Test Offering Simultaneous Scientific Advice

By Vibha Sharma 27 Jan 2020

An EU pilot project will assess whether there is sufficient demand from companies to obtain simultaneous scientific advice from EU national competent authorities.

View article
HBW Insight

OTC Drug Oversight By US FDA Split Among Two Divisions In Reorganization

By Malcolm Spicer 27 Jan 2020

CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.

View article
HBW Insight

Polish Industry Fighting Against Advertising Tax On Supplements

By Tom Gallen 27 Jan 2020

Advertising dietary supplements in Poland will incur a new tax under proposals from the country's Ministry of Health. While the government claims the motivation is to promote healthy eating choices, industry says supplements have been unfairly linked to poor dietary choices without evidence.

View article
Generics Bulletin

Celltrion Sets Out Strategy For China

By David Wallace 27 Jan 2020

Celltrion has unveiled plans to construct a biologics plant in Wuhan, China, as well as setting up a direct sales network in the country, as part of its wider global strategy that also involves launching a new biosimilar every year to 2030.

View article
Generics Bulletin

Coherus Is Confident After US Ranibizumab Filing

By Aidan Fry 27 Jan 2020

Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.

Topic Biosimilars Deal trends

View opinion
Scrip

Scrip's Rough Guide On The State Of RNAi

By Daniel Chancellor 27 Jan 2020

The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.

View analysis
Scrip

Health Sector On High Alert As Wuhan Coronavirus Spreads

By Brian Yang 27 Jan 2020

The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”

View analysis
Scrip

J.P. Morgan Conference Updates

By Mandy Jackson 22 Jan 2020

Updates and coverage of the 2020 J.P. Morgan Healthcare Conference in San Francisco.

View article
Pink Sheet

A Visual Guide To US FDA's Evolutionary Decade In Review

By Brenda Sandburg 16 Jan 2020

An interactive timeline shows the news of the past decade and the evolution of US FDA policies. Click on each year for a full list of events and see the accompanying article.

Topic FDA Policy and regulation

View analysis
Scrip

O’Day Lays Out Plan For Gilead’s Continued HIV Dominance

By Joseph Haas 15 Jan 2020

Biktarvy’s powerful sales growth and the potential of a first-in-class capsid inhibitor in both prevention and heavily treatment-experienced patients are key to Gilead’s plan for staying on top in HIV.

View analysis